trial · primary record
Dexamethasone
Multiple Myeloma Refractory
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2032-12 |
| Primary endpoint | Proportion of patients achieving minimal residual disease (MRD) negativity. |
| Registry ID | NCT07901868 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:19.272Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07901868
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- DEXAMETHASONE · approval
- DEXAMETHASONE · approval
- DEXAMETHASONE · approval
- Dexamethasone · compound